본문 바로가기
KERD
논문KCI 등재

Phenotypic and Genotypic Analysis of Anti-Tuberculosis Drug Resistance in Mycobacterium tuberculosis Isolates in Myanmar

0

조회

0

다운로드

1

인용

0

참고문헌

키워드

주제분류병리학

초록

Background: Tuberculosis (TB) is one of the most serious health problems in Myanmar. Because TB drug resistance is associated with genetic mutation(s) relevant to responses to each drug, genotypic methods for detecting these mutations have been proposed to overcome the limitations of classic phenotypic drug susceptibility testing (DST). We explored the current estimates of drug-resistant TB and evaluated the usefulness of genotypic DST in Myanmar. Methods: We determined the drug susceptibility of Mycobacterium tuberculosis isolated from sputum smear-positive patients with newly diagnosed pulmonary TB at two main TB centers in Myanmar during 2013 by using conventional phenotypic DST and the GenoType MTBDRplus assay (Hain Lifescience, Germany). Discrepant results were confirmed by sequencing the genes relevant to each type of resistance (rpoB for rifampicin; katG and inhA for isoniazid). Results: Of 191 isolates, phenotypic DST showed that 27.7% (n=53) were resistant to at least one first-line drug and 20.9% (n=40) were resistant to two or more, including 18.3% (n=35) multidrug-resistant TB (MDR-TB) strains. Monoresistant strains accounted for 6.8% (n=13) of the samples. Genotypic assay of 189 isolates showed 17.5% (n=33) MDR-TB and 5.3% (n=10) isoniazid-monoresistant strains. Genotypic susceptibility results were 99.5% (n=188) concordant and agreed almost perfectly with phenotypic DST (kappa=0.99; 95% confidence interval 0.96-1.01). Conclusions: The results highlight the burden of TB drug resistance and prove the usefulness of the genotypic DST in Myanmar.

Abstract

Background: Tuberculosis (TB) is one of the most serious health problems in Myanmar. Because TB drug resistance is associated with genetic mutation(s) relevant to responses to each drug, genotypic methods for detecting these mutations have been proposed to overcome the limitations of classic phenotypic drug susceptibility testing (DST). We explored the current estimates of drug-resistant TB and evaluated the usefulness of genotypic DST in Myanmar. Methods: We determined the drug susceptibility of Mycobacterium tuberculosis isolated from sputum smear-positive patients with newly diagnosed pulmonary TB at two main TB centers in Myanmar during 2013 by using conventional phenotypic DST and the GenoType MTBDRplus assay (Hain Lifescience, Germany). Discrepant results were confirmed by sequencing the genes relevant to each type of resistance (rpoB for rifampicin; katG and inhA for isoniazid). Results: Of 191 isolates, phenotypic DST showed that 27.7% (n=53) were resistant to at least one first-line drug and 20.9% (n=40) were resistant to two or more, including 18.3% (n=35) multidrug-resistant TB (MDR-TB) strains. Monoresistant strains accounted for 6.8% (n=13) of the samples. Genotypic assay of 189 isolates showed 17.5% (n=33) MDR-TB and 5.3% (n=10) isoniazid-monoresistant strains. Genotypic susceptibility results were 99.5% (n=188) concordant and agreed almost perfectly with phenotypic DST (kappa=0.99; 95% confidence interval 0.96-1.01). Conclusions: The results highlight the burden of TB drug resistance and prove the usefulness of the genotypic DST in Myanmar.

참고문헌 (22)

  1. Global Tuberculosis Report 2012, "World Health Organization", WHO, ~, pp.WHO (2012), HTM[DOI]
  2. Agonafir M, "Phenotypic and genotypic analysis of multidrug-resistant tuberculosis in Ethiopia", Int J Tuberc Lung Dis, 14, pp.1259~1265 (2010)
  3. "Policy Statement. Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB)" (2008)[URL]
  4. Hillemann D, "Use of the genotype MTBDR assay for rapid detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis complex isolates", J Clin Microbiol, 43, pp.3699~3703 (2005)
  5. Laboratory services in tuberculosis control. Culture Part III 1998, "World Health Organization", WHO, ~, pp.WHO (1998), TB[DOI]
  6. "Guidelines for surveillance of drug resistance in tuberculosis. WHO/CDS/CSR/RMD/2003" (2003)[URL]
  7. Viera AJ, "Understanding interobserver agreement: the kappa statistic", Fam Med, 37, pp.360~363 (2005)
  8. World Health Organization, "Management of MDR-TB: a field guide. WHO", HTM, 2008.402a, pp.WHO, 2009[DOI]
  9. Ti T, "Magnitude of the MDR-TB problem among patients attending Yangon Divisional TB Centre, Myanmar", Myanmar Med J, 50, pp.2~7 (2007)
  10. Phyu S, "Drug-resistant Mycobacterium tuberculosis among new tuberculosis patients,Yangon, Myanmar", Emerg Infect Dis, 9, pp.274~276 (2003)
  11. Ti T, "National anti-tuberculosis drug resistance survey, 2002 in Myanmar", Int J Tuberc Lung Dis, 10, pp.1111~1116 (2006)
  12. Aung WW, "Study of drug resistant cases among new pulmonary tuberculosis patients attending a tuberculosis center, Yangon, Myanmar", Southeast Asian J Trop Med Public Health, 38, pp.104~110 (2007)
  13. Annual Report 2012, "National Tuberculosis Programme, Myanmar", Ministry of Health, Myanmar: NTP, ~ (2012)
  14. Bai GH, "Trends of anti-tuberculosis drug resistance in Korea, 1994-2004", Int J Tuberc Lung Dis, 11, pp.571~576 (2007)
  15. Telenti A, "Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis", Lancet, 341, pp.647~650 (1993)
  16. Ozturk CE, "Molecular analysis of isoniazid, rifampin and streptomycin resistance in Mycobacterium tuberculosis isolates from patients with tuberculosis in Düzce, Turkey", Jpn J Infect Dis, 58, pp.309~312 (2005)
  17. Ahmad S, "Molecular diagnosis of drug resistant tuberculosis", Kuwait Med J, 33, pp.120~126 (2001)
  18. Baker LV, "Molecular analysis of isoniazid-resistant Mycobacterium tuberculosis isolates from England and Wales reveals the phylogenetic significance of the ahpC-46A polymorphism", Antimicrob Agents Chemother, 49, pp.1455~1464 (2005)
  19. Hillemann D, "Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens", J Clin Microbiol, 45, pp.2635~2640 (2007)
  20. Causse M, "Evaluation of new GenoType MTBDRplus for detection of resistance in cultures and direct specimens of Mycobacterium tuberculosis", Int J Tuberc Lung Dis, 12, pp.1456~1460 (2008)
  21. Huyen MN, "Validation of the GenoTypenMTBDRplus assay for the diagnosis of multidrug resistant tuberculosis in South Vietnam", BMC Infect Dis, 10, pp.149~ (2010)
  22. Tessema B, "Analysis of gene mutations associated with isoniazid, rifampicin and ethambutol resistance among Mycobacterium tuberculosis isolates from Ethiopia", BMC Infect Dis, pp.12~37 (2012)

관련 논문AI추천

Evaluation of the QuantaMatrix Multiplexed Assay Platform for Molecular Diagnosis of Multidrug- and Extensively Drug-Resistant Tuberculosis Using Clinical Strains Isolated in Myanmar장철훈, Dasom Hwang, HyeyoungLee, Jongseok Lee, Phyu Win Ei, Seoyong Kim, Yeun Kim, Yunhee Chang대한진단검사의학회 · Annals of Laboratory Medicine2020 · 제40권 제2호Detection of Isoniazid and Rifampicin Resistance by Sequencing of katG, inhA, and rpoB Genes in Korea강성기, 배혜경, 이은희, 조은해대한진단검사의학회 · Annals of Laboratory Medicine2009 · 제29권 제5호Determining Genotypic Drug Resistance by Ion Semiconductor Sequencing With the Ion AmpliSeq™ TB Panel in Multidrug-Resistant Mycobacterium tuberculosis Isolates박건, 김경종, 박준홍, 신소영, 신소윤, 임춘화대한진단검사의학회 · Annals of Laboratory Medicine2018 · 제38권 제4호Drug susceptibility testing for Mycobacterium tuberculosis: a narrative review김창기대한임상미생물학회 · Annals of Clinical Microbiology2025 · 제28권 제4호객담 검체에서 다제내성 결핵균의 검출을 위한 GenoType® MTBDRplus의 평가김미나, 성흥섭, 심태선, 안동희, 정태동, 지현숙대한진단검사의학회 · Laboratory Medicine Online2011 · 제1권 제1호Detection of Rifampicin- and Isoniazid-Resistant Mycobacterium tuberculosis Using the Quantamatrix Multiplexed Assay Platform System어영, 김서용, 왕혜영, 이종석, 이혜영, 조은진대한진단검사의학회 · Annals of Laboratory Medicine2018 · 제38권 제6호

이 간행물의 다른 논문 (17건)